Companion Animal Arthritis Market Size, Share & Trends Analysis Report By Animal Type (Dogs, Cats, Others), By Indication (Osteoarthritis, Other Arthritis), By Treatment (Medication, Others Medications, Supplements, Other Treatment), By Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies, Online Stores, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Companion Animal Arthritis Market Size

The global companion animal arthritis market size was valued at USD 4.02 billion in 2024 and is projected to grow from USD 4.63 billion in 2025 to reach USD 8.3 billion by 2033, exhibiting a CAGR of 7.21% during the forecast period (2025-2033).

Arthritis is one of the most common conditions affecting companion animals, particularly cats and dogs. When left untreated, it can lead to severe inflammation and discomfort. In recent years, there has been a notable rise in the number of animals suffering from arthritis, largely due to increasing pet populations and growing awareness of animal health.

• According to a November 2022 report from the American Veterinary Medical Association, the dog population in the U.S. rose from 76.8 million in 2016 to 83.7 million in 2020, while the cat population increased from 58.4 million to 60 million over the same period.

This surge in pet populations has driven greater attention to animal healthcare, including arthritis treatment. Increased spending on pet care, pet insurance, and adoption rates have all contributed to this trend. In 2021, pet care expenditure in the U.S. grew to USD 123 billion, a significant increase from USD 53 billion in 2012, as reported by the Insurance Information Institute.

• Similarly, in Europe, the FEDIAF report highlighted that over EUR 21.8 billion was spent on pet food products in 2020. These trends underscore the growing importance of pet health and the rising demand for treatments such as those for arthritis in companion animals.

Companion Animal Arthritis Market Trends

Growing demand for natural and nutraceutical products

The increasing demand for natural and nutraceutical products in the global companion animal arthritis market reflects a broader shift toward holistic and preventive health approaches for pets. Pet owners are increasingly seeking natural remedies, such as chondroitin sulfate, turmeric, and omega-3 fatty acids, to manage arthritis symptoms in their pets.

These products are perceived as safer alternatives to traditional pharmaceuticals, often with fewer side effects, and are valued for their ability to support joint health, reduce inflammation, and enhance mobility. This trend is driven by pet owners' growing awareness of the long-term effects of conventional medications and their desire for safer, more sustainable solutions.

• For example, in April 2024, Novastell, a leading supplier of functional and nutritional additives, was acquired by SOPHIM. This acquisition, which was finalized in September 2023, signals the increasing focus on nutraceutical products within the pet health industry, reflecting a growing demand for products that promote wellness in companion animals.

Increasing use of integrated treatment approaches, combining pharmaceuticals and physical therapies

The adoption of integrated treatment strategies for managing arthritis in companion animals marks a significant shift toward more personalized and comprehensive pet care. This approach blends the advantages of conventional pharmaceuticals, such as anti-inflammatory drugs and pain management solutions, with physical therapies aimed at enhancing joint health and mobility.

Techniques like hydrotherapy, massage, and tailored exercise regimens complement medication by improving joint function, alleviating stiffness, and boosting circulation. By merging medical treatments with therapeutic practices, veterinarians can deliver a holistic care plan that not only mitigates pain and inflammation but also addresses the root causes of restricted movement.

• For example, in August 2024, Recursion and Exscientia entered into a definitive agreement to become leaders in technology-enabled drug discovery, enhancing the potential for more innovative and integrated approaches to treat companion animal conditions, including arthritis. This partnership represents a shift towards more advanced and effective treatment methods in the veterinary field.

Companion Animal Arthritis Market Growth Factors

Increasing prevalence of arthritis in aging pets

The rising prevalence of arthritis in aging pets is a key driver of the companion animal arthritis market. Similar to humans, pets experience joint degeneration as they age, with osteoarthritis being particularly common in older dogs and cats. This condition leads to pain, stiffness, and reduced mobility, which significantly impacts their quality of life.

As a result, there is a growing focus on the treatment and management of arthritis in aging pets, driving research and the development of medications, supplements, and therapeutic options.

• For example, the Morris Animal Foundation reports that osteoarthritis affects over 14 million adult dogs in the U.S., highlighting the scale of the issue and the demand for effective arthritis care in companion animals.

Market Restraining Factors

Potential side effects of some medications

The potential side effects of certain medications are a significant restraint on the growth of the market. Although NSAIDs and corticosteroids are commonly used to manage arthritis pain and inflammation, they carry risks such as gastrointestinal irritation, liver damage, kidney issues, and allergic reactions, especially in pets with pre-existing conditions.

• For instance, studies have reported that long-term use of NSAIDs in dogs can lead to vomiting, diarrhea, and even gastrointestinal ulcers. These risks often lead pet owners and veterinarians to reconsider pharmaceutical options, particularly in cases of pets with multiple health issues or drug sensitivities.

As a result, there is a growing interest in alternative treatments, such as nutraceuticals and physical therapies, which are perceived as safer and have fewer or no side effects. The concern over the safety of conventional medications drives the demand for safer, more natural alternatives in the market.

Market Opportunities

Development of new biological and regenerative therapies

New biologic and regenerative therapies are creating significant opportunities in the market by offering long-term relief through tissue repair, inflammation reduction, and cartilage regeneration. Treatments such as stem cell therapy, platelet-rich plasma (PRP) therapy, and gene therapy target not only the symptoms but also the root causes of arthritis.

For example, a study published in Veterinary Therapeutics examined the effects of stem cell therapy on dogs with osteoarthritis. The study involved 60 dogs suffering from arthritis in their hips, knees, or elbows. The dogs were treated with autologous mesenchymal stem cells (derived from their own bone marrow), which were injected into their affected joints. The results showed significant improvements in both pain management and mobility, with over 70% of the dogs reporting reduced discomfort and improved joint function six months after treatment.

Similarly, PRP therapy, which uses the pet's own blood to deliver growth factors and promote healing, has shown positive outcomes in treating joint injuries and arthritis. These therapies not only provide less invasive, more durable solutions but also pave the way for more personalized arthritis management in pets, which could reshape the market landscape.

Regional Insights

North America: Dominant region with 33.6% market share

North America, particularly the United States, leads the global market due to its well-established pet care industry, high pet ownership rates, and increasing focus on pet health. Awareness among pet owners about arthritis, combined with the importance of early diagnosis and treatment, has significantly boosted demand for arthritis care.

North American veterinary practices are equipped with advanced diagnostic tools and offer a range of treatment options, including biologic therapies and regenerative medicine, contributing to the market's dominance. The pet humanization trend, where pets are treated as family members, further drives investment in high-quality healthcare, fueling the demand for arthritis treatments.

Asia Pacific: Fastest growing region with the highest market CAGR

The Asia-Pacific is expected to be the fastest-growing region in the global market. This growth is driven by increasing pet ownership, particularly in countries like China and India, where pets are becoming an integral part of families. As pet care awareness and disposable income rise in these emerging markets, there is a growing demand for specialized veterinary care and arthritis treatments. Moreover, the adoption of more advanced veterinary practices and treatments in Asia-Pacific, alongside the increasing availability of affordable medications, will contribute to the rapid market expansion in the region.

Country Insights

The global market is witnessing growth globally, with certain key countries making significant contributions due to their healthcare infrastructure, rising demand for plasma-based therapies, and increasing plasma donation campaigns. Developed countries like the United States, Germany, and Japan lead the market due to their advanced healthcare systems, high prevalence of autoimmune diseases, and strong plasma collection infrastructure.

Below is the analysis of key countries impacting the market:

• US.- In the United States, the American Veterinary Medical Association (AVMA) estimates that around 118,624 licensed veterinarians were practicing in 2020, predominantly serving companion animals. This large network of veterinarians plays a critical role in addressing the growing demand for pet healthcare, including arthritis management for pets.As pet ownership continues to rise, particularly among dogs and cats, veterinary services are essential in providing specialized treatments and therapies for a variety of conditions, including arthritis, ensuring pets live healthier lives.
• Canada- Canada boasts a high level of pet ownership, with 61% of households owning a pet, surpassing the global average. Among these, cats and dogs are the most popular, with 23% of households owning cats and 20% owning dogs. In 2022, there were approximately 8.5 million cats and 7.9 million dogs in the country.This widespread pet ownership has led to a growing demand for veterinary services, including arthritis treatments, as more pet owners seek ways to improve the health and comfort of their beloved companions.
• India- India’s companion animal market is rapidly growing, with increasing investment from companies looking to innovate and capture market share. Notable investments include L Catterton's USD 60 million in Drools, Verlinvest and Sequoia Capital India's USD 37 million in HUFT, and RPSG Capital Ventures' USD 15 million in Supertails.These investments signal the emergence of a competitive market, with an increasing focus on developing products and services to support pet health, including treatments for common conditions like arthritis.
• Japan- Japan's aging population and declining birthrate are reshaping the country’s demographics, creating new opportunities within the pet care industry. As more people look for companionship from pets, particularly dogs and cats, the demand for pet healthcare services, including arthritis management, is growing.Moreover, the increasing focus on pet wellness aligns with the country’s evolving healthcare landscape, making Japan a promising market for innovative pet care solutions aimed at improving the quality of life for aging companion animals.
• China: China’s pet industry is booming, with over one million businesses involved in the pet industry chain. The majority of pets in China are dogs (51%) and cats (46%), while a smaller percentage includes fish, reptiles, rodents, and birds. As the market expands, pet owners are becoming more invested in the health and well-being of their pets, increasing the demand for specialized veterinary services.
• UK: In the UK, the pet care sector continues to grow, with significant developments such as the opening of the first animal healthcare start-up incubator at the University of Surrey’s Veterinary School in April 2024. This incubator aims to support early-stage companies focused on improving animal health and well-being.Such initiatives are fostering innovation in the industry, particularly in the development of new solutions for common pet health issues like arthritis, driving the demand for advanced veterinary care and treatments.
• UAE: In April 2022, Abu Dhabi launched a major project to enhance its veterinary services, which includes the opening of two modern hospitals, a vaccine manufacturing plant, and state-of-the-art veterinary facilities. This initiative solidifies Abu Dhabi’s position as a leading provider of veterinary care in the MEA region, particularly for horses and camels, while also contributing to advancements in animal healthcare solutions, including arthritis treatments.

Segmentation Analysis

The global companion animal arthritis is segmented into animal type, indication, treatment, and distribution channel.

By Animal Type

Plasma Animal Type Segment Holds The Largest Market Share.

Dogs are the dominant segment in the global companion animal arthritis industry, particularly because they are more prone to arthritis, especially large breeds and older dogs. The physical stress of their weight and activity levels often leads to joint injuries and arthritis. As dogs require regular exercise to maintain their health, managing arthritis becomes essential to preserving their quality of life. This demand for arthritis treatments is driven by the high incidence of joint problems in dogs, making them the primary focus of arthritis management in the companion animal sector.

By Indication

Osteoarthritis Segment Dominates The Market Share.

Osteoarthritis (OA) is the leading indication in the global market for companion animal arthritis, primarily affecting older pets. It is characterized by the deterioration of cartilage in the joints, causing pain, inflammation, and reduced mobility. As pets live longer, the incidence of OA continues to rise, especially in dogs and cats. The aging process and wear-and-tear on joints contribute to the development of osteoarthritis, making it the most prevalent form of arthritis among companion animals. This condition remains the primary driver of the arthritis treatment market due to its high frequency in older animals.

By Treatment

Plasma Donation Segment Holds The Largest Market Share.

Nonsteroidal anti-inflammatory drugs (NSAIDs) dominate the companion animal arthritis treatment market due to their effectiveness in managing pain and inflammation, which are the main symptoms of arthritis. NSAIDs are commonly prescribed for both chronic and acute arthritis cases, particularly in older pets. Compared to more complex biological therapies, these drugs are preferred for their affordability and ease of use. With ongoing research, newer NSAIDs with fewer side effects have been developed, allowing for longer-term use and improved safety, reinforcing their position as the treatment of choice for managing arthritis.

By Distribution Channel

Veterinary Hospitals & Clinics Segment Holds The Largest Market Share.

Veterinary hospitals and clinics are the leading distribution channels in the global companion animal arthritis industry. These establishments are the first point of contact for pet owners seeking arthritis diagnosis and treatment. Veterinary professionals provide a range of services, including diagnostic tests, medications, biologic therapies, and physical treatments like physiotherapy. With access to advanced diagnostic tools such as X-rays and MRIs, these clinics are critical in identifying and managing arthritis, ensuring pets receive the best possible care and follow-up treatments for improved mobility and quality of life.

Company Market Share

The global market is competitive in nature, with the presence of large multinational and small & mid-sized companies. The companies are involved in the development & launch of innovative products, partnerships, competitive pricing strategies, product and service expansion, sales and marketing initiatives, and mergers & acquisitions.

Zoetis: An Emerging Market Player

Zoetis, a global leader in animal health, is making significant strides in the companion animal healthcare market, particularly in the management of arthritis. The company’s focus on innovative solutions for pets, including advanced biologic treatments and pain management options, has positioned Zoetis as a key player in the emerging pet health sector.

Recent developments at Zoetis include:

• For instance, in Jan 2022, Zoetis received FDA approval for Solentia, a monoclonal antibody injection in the U.S. This frunevetmab injection is intended for osteoarthritis pain in cats.

Recent Developments

• August 2024 -A recent study has introduced a promising biomaterial designed to treat arthritis by promoting the growth of new cartilage. The study was conducted by researchers from the University of California, Berkeley. This bioactive material, resembling a rubbery substance, mimics natural cartilage and has been shown to regenerate high-quality cartilage in sheep knee joints within six months.

Analyst Opinion

As per our analyst, the companion animal arthritis market is experiencing significant growth, driven by increasing pet ownership, heightened awareness of pet health, and advancements in veterinary care. As the pet population ages, arthritis has become more prevalent, fueling the demand for innovative treatments and effective pain management solutions. Leading companies are investing heavily in the research and development of new drugs, nutraceuticals, and joint supplements tailored specifically for animals.

Additionally, less invasive therapies, such as regenerative medicine and stem cell injections, are gaining popularity as effective alternatives to traditional treatment methods. Pet owners are also showing greater willingness to invest in premium pet insurance and veterinary care, further driving the market's expansion.

However, challenges such as high medical costs and limited awareness in developing countries may pose obstacles to market growth. Moving forward, the focus will likely be on improving drug formulations, forging collaborations with veterinary clinics, and implementing educational programs to promote early detection and treatment.